<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article">
  <?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?>
  <?DTDIdentifier.IdentifierType public?>
  <?SourceDTD.DTDName journalpublishing.dtd?>
  <?SourceDTD.Version 2.3?>
  <?ConverterInfo.XSLTName jp2nlmx2.xsl?>
  <?ConverterInfo.Version 2?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Int J Chron Obstruct Pulmon Dis</journal-id>
      <journal-id journal-id-type="publisher-id">International Journal of COPD</journal-id>
      <journal-title-group>
        <journal-title>International Journal of Chronic Obstructive Pulmonary Disease</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1176-9106</issn>
      <issn pub-type="epub">1178-2005</issn>
      <publisher>
        <publisher-name>Dove Medical Press</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">3119104</article-id>
      <article-id pub-id-type="pmid">21697993</article-id>
      <article-id pub-id-type="doi">10.2147/COPD.S18181</article-id>
      <article-id pub-id-type="publisher-id">copd-6-289</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Role of clinical questionnaires in optimizing everyday care of chronic obstructive pulmonary disease</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Jones</surname>
            <given-names>Paul W</given-names>
          </name>
          <xref ref-type="aff" rid="af1-copd-6-289">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="c1-copd-6-289"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Price</surname>
            <given-names>David</given-names>
          </name>
          <xref ref-type="aff" rid="af2-copd-6-289">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>van der Molen</surname>
            <given-names>Thys</given-names>
          </name>
          <xref ref-type="aff" rid="af3-copd-6-289">
            <sup>3</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="af1-copd-6-289"><label>1</label>Cardiac and Vascular Medicine, St George&#x2019;s, University of London, UK;</aff>
      <aff id="af2-copd-6-289"><label>2</label>Centre of Academic Primary Care, University of Aberdeen, UK;</aff>
      <aff id="af3-copd-6-289"><label>3</label>Department of General Practice, University Medical Center Groningen, The Netherlands</aff>
      <author-notes>
        <corresp id="c1-copd-6-289">Correspondence: Paul W Jones, Cardiac and Vascular Medicine, St George&#x2019;s, University of London, Cranmer Terrace, SW17 0RE, UK, Tel +44 020 8725 5372, Fax +44 020 8725 5955, Email <email>pjones@sgul.ac.uk</email></corresp>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2011</year>
      </pub-date>
      <!--Dove Press titles changed from ppub to collections in 2009.
								Fake ppub written to satisfy Coll Date Type=ppub-->
      <pub-date pub-type="ppub">
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>26</day>
        <month>5</month>
        <year>2011</year>
      </pub-date>
      <volume>6</volume>
      <fpage>289</fpage>
      <lpage>296</lpage>
      <history>
        <date date-type="received">
          <day>25</day>
          <month>5</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2011 Jones et al, publisher and licensee Dove Medical Press Ltd.</copyright-statement>
        <copyright-year>2011</copyright-year>
        <license>
          <license-p>This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Chronic obstructive pulmonary disease (COPD) is a leading cause of disability in all its stages, and death in patients with moderate or severe obstruction. At present, COPD is suboptimally managed; current health is often not measured properly and hardly taken into account in management plans, and the future risk for patients with regard to health status and quality of life is not being evaluated. This review addresses the effect of COPD on the lives of patients and examines ways in which existing assessment tools meet physicians&#x2019; needs for a standardized, simple method to measure consistently the full impact of COPD on patients in routine clinical practice. Current assessment of COPD severity tends to focus on airflow limitation, but this does not capture the full impact of the disease and is not well correlated with patient perception of symptoms and health-related quality of life. Qualitative studies have demonstrated that patients usually consider COPD impact in terms of frequency and severity of symptoms, and physical and emotional wellbeing. However, patients often have difficulty expressing their disease burden and physicians generally have insufficient time to collect this information. Therefore, it is important that methods are implemented to help generate a more complete understanding of the impact of COPD. This can be achieved most efficiently using a quick, reliable, and standardized measure of disease impact, such as a short questionnaire that can be applied in daily clinical practice. Questionnaires are precision instruments that contribute sensitive and specific information, and can potentially help physicians provide optimal care for patients with COPD. Two short, easy-to-use, specific measures, ie, the COPD Assessment Test and the Clinical COPD Questionnaire, enable physicians to assess patients&#x2019; health status accurately and improve disease management. Such questionnaires provide important measurements that can assist primary care physicians to capture the impact of COPD on patients&#x2019; daily lives and wellbeing, and improve long-term COPD management.</p>
      </abstract>
      <kwd-group>
        <kwd>chronic obstructive pulmonary disease</kwd>
        <kwd>COPD assessment test</kwd>
        <kwd>disease management</kwd>
        <kwd>health status</kwd>
        <kwd>quality of life</kwd>
        <kwd>questionnaire</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>Chronic obstructive pulmonary disease (COPD) is a major public health problem of high and increasing prevalence,<xref ref-type="bibr" rid="b1-copd-6-289">1</xref>&#x2013;<xref ref-type="bibr" rid="b5-copd-6-289">5</xref> and is a leading cause of disability in all its stages<xref ref-type="bibr" rid="b6-copd-6-289">6</xref>,<xref ref-type="bibr" rid="b7-copd-6-289">7</xref> and death in patients with moderate or severe obstruction.<xref ref-type="bibr" rid="b8-copd-6-289">8</xref>&#x2013;<xref ref-type="bibr" rid="b10-copd-6-289">10</xref> COPD imposes a profound burden on patients, including medical emergencies, hospitalizations, work absenteeism, and activity limitations. Ultimately, this has a significant physical and emotional impact on patients.<xref ref-type="bibr" rid="b11-copd-6-289">11</xref></p>
      <p>COPD, as defined by airflow limitation, is often underdiagnosed<xref ref-type="bibr" rid="b12-copd-6-289">12</xref>&#x2013;<xref ref-type="bibr" rid="b14-copd-6-289">14</xref> and undertreated,<xref ref-type="bibr" rid="b15-copd-6-289">15</xref> leading to poor quality of life for patients.<xref ref-type="bibr" rid="b16-copd-6-289">16</xref> Current assessments of COPD severity focus on the amount of air that patients can forcibly exhale from their lungs in the first second of a forced exhalation (FEV<sub>1</sub>), but this alone does not capture the full impact of the disease.<xref ref-type="bibr" rid="b17-copd-6-289">17</xref> As a consequence, patients with COPD are often suboptimally managed.<xref ref-type="bibr" rid="b18-copd-6-289">18</xref>,<xref ref-type="bibr" rid="b19-copd-6-289">19</xref> The future risk for patients with COPD with regard to health status and quality of life is not currently being evaluated routinely, but it is likely that this will provide a marker of both current impact and future risk in these patients.<xref ref-type="bibr" rid="b20-copd-6-289">20</xref>&#x2013;<xref ref-type="bibr" rid="b24-copd-6-289">24</xref></p>
      <p>Improved COPD management requires a range of patient assessments, including lung function, exacerbation episodes, exercise tolerance, and impact on health status. However, patients often have difficulty expressing the burden of their disease and physicians generally do not have sufficient time to collect this information. Therefore, it is important that methods are implemented to enable clinicians to reach a more complete understanding of the impact of the disease on their patients and identify specific needs. The most efficient way to achieve this is to use a quick, reliable, and standardized measure of disease impact, such as a short questionnaire, that can be applied in daily clinical practice to provide physicians with additional useful information. Validated patient-reported outcomes, eg, measurements of health status (health-related quality of life [HRQoL]), or functional status are now recognized as being key in capturing the patient&#x2019;s experience of important aspects of health in chronic disease.<xref ref-type="bibr" rid="b25-copd-6-289">25</xref> Use of these measures will enable physicians to determine what is really important to the individual patient and highlight differences between patients.</p>
      <p>In conjunction with patient-reported measures, health care systems need to be more organized and focused towards meeting the current and future needs of patients with COPD. Patients with chronic disease require both regular clinician assessments and self-management. Application of the chronic care model, which includes fundamental elements (eg, the community, health care system, and patient self-management) needed to support high-quality care for patients with chronic disease, could potentially improve COPD management.<xref ref-type="bibr" rid="b26-copd-6-289">26</xref>&#x2013;<xref ref-type="bibr" rid="b28-copd-6-289">28</xref></p>
      <p>The management of COPD is now directed towards symptomatic benefit, in terms of improved HRQoL and exercise tolerance, and risk reduction (eg, exacerbations, hospital admissions, and death). Assessment of COPD risk can now be done in routine clinical practice using simple multidimensional prognostic scaling systems, such as the DOSE index.<xref ref-type="bibr" rid="b29-copd-6-289">29</xref> The aim of this review, however, is to address the impact of COPD on patients&#x2019; lives and to discuss ways in which the new assessment tools can meet physicians&#x2019; needs for a standardized, simple method to measure consistently the full impact of COPD on patients in routine clinical practice.</p>
    </sec>
    <sec sec-type="subjects|discussion">
      <title>Measuring impact of COPD on patients</title>
      <p>The burden of COPD on patients and their families is high.<xref ref-type="bibr" rid="b13-copd-6-289">13</xref>,<xref ref-type="bibr" rid="b30-copd-6-289">30</xref>&#x2013;<xref ref-type="bibr" rid="b32-copd-6-289">32</xref> Furthermore, it is not limited to patients with severe COPD, but is also very prominent in younger patients with only mild or moderate airway obstruction, limiting them in their daily lives.<xref ref-type="bibr" rid="b33-copd-6-289">33</xref> In general, patients have a restricted understanding of both the extent of their loss of pulmonary function and the severity of their COPD. In the Confronting COPD International Survey, patients&#x2019; perceptions of the severity of their COPD did not consistently correspond with the degree of severity indicated by the Medical Research Council (MRC) dyspnea (breathlessness) scale.<xref ref-type="bibr" rid="b16-copd-6-289">16</xref> In addition, most patients do not appear to place the same level of importance on their exacerbation episodes as health care providers,<xref ref-type="bibr" rid="b34-copd-6-289">34</xref> and a recent study showed that patients generally report smaller changes in HRQoL outcome measures as more clinically meaningful than do physicians.<xref ref-type="bibr" rid="b35-copd-6-289">35</xref> Thus, the provision of measures to document clinical outcomes can help both patients and health care providers improve their knowledge about the impact of COPD on patient health.</p>
      <p>Surveys have indicated that patients usually consider the impact of COPD in terms of symptom frequency and severity, and physical and emotional wellbeing.<xref ref-type="bibr" rid="b16-copd-6-289">16</xref> In the Confronting COPD in America survey, 90% of individuals with COPD experienced symptoms either every day or most days during their worst three-month period in the past year (<xref ref-type="fig" rid="f1-copd-6-289">Figure 1</xref>).<xref ref-type="bibr" rid="b36-copd-6-289">36</xref> Also, patients use language such as &#x201C;good&#x201D; and &#x201C;bad&#x201D; days to define how COPD influences their HRQoL, so patients&#x2019; self-reported assessments are important when evaluating the intensity of symptoms, such as dyspnea and fatigue, and their impact on HRQoL.<xref ref-type="bibr" rid="b37-copd-6-289">37</xref></p>
    </sec>
    <sec>
      <title>Changing health status</title>
      <p>A study in patients with stable COPD showed that changes in health status assessed by patient-reported measures (eg, the St George&#x2019;s Respiratory Questionnaire [SGRQ], Chronic Respiratory Questionnaire [CRQ], MRC dyspnea scale, and the Hospital Anxiety and Depression Scale [HADS]) worsened significantly over time.<xref ref-type="bibr" rid="b38-copd-6-289">38</xref> However, deteriorations in patient-reported outcomes (eg, symptoms, limitation of daily activities, and wellbeing) showed only a weak correlation with changes in physiological indices such as FEV<sub>1</sub> and maximal oxygen uptake measured at peak exercise.<xref ref-type="bibr" rid="b38-copd-6-289">38</xref> Those authors concluded that to capture the overall deterioration in patients&#x2019; health status due to COPD, patient-reported outcomes should be followed independently of physical outcomes.<xref ref-type="bibr" rid="b38-copd-6-289">38</xref></p>
    </sec>
    <sec sec-type="subjects">
      <title>Challenges in providing chronic care for patients with COPD</title>
      <p>During a consultation, patients tend to understate their disease severity, under-report COPD exacerbations, and do not convey the impact of the disease on their quality of life. In addition, patients often only present to their physicians when their condition has progressed significantly leading to a reduced HRQoL.<xref ref-type="bibr" rid="b14-copd-6-289">14</xref>,<xref ref-type="bibr" rid="b39-copd-6-289">39</xref> Consequently, there is a need to assess patients&#x2019; health status to enable optimal disease management.</p>
    </sec>
    <sec>
      <title>Clinical assessment questionnaires in COPD</title>
      <p>Physicians need to consider several factors when assessing patients with COPD. The impact of COPD depends not only on the degree of airflow limitation but also on the severity of symptoms, systemic effects, and any comorbidities present.<xref ref-type="bibr" rid="b2-copd-6-289">2</xref>,<xref ref-type="bibr" rid="b31-copd-6-289">31</xref> When a patient experiences an exacerbation they often require several weeks of recovery;<xref ref-type="bibr" rid="b24-copd-6-289">24</xref> sustained worsening of symptoms can also have a significant impact on patients&#x2019; HRQoL and mortality.<xref ref-type="bibr" rid="b40-copd-6-289">40</xref>&#x2013;<xref ref-type="bibr" rid="b44-copd-6-289">44</xref> Importantly, reductions in objective pulmonary function measurements, such as FEV<sub>1</sub>, are not well correlated with patients&#x2019; perception of symptoms and HRQoL (<xref ref-type="fig" rid="f2-copd-6-289">Figure 2</xref>).<xref ref-type="bibr" rid="b17-copd-6-289">17</xref>,<xref ref-type="bibr" rid="b45-copd-6-289">45</xref> When managing patients with COPD it is therefore necessary to measure both pulmonary function and HRQoL.</p>
      <p>Physicians require help in realizing the full impact of COPD on their patients. Qualitative studies showed that patients with COPD have difficulty placing themselves along a continuum of disease severity and relating their severity to that of other patients with COPD. During development of the COPD Assessment Test (CAT), patients indicated that they would like to have a method available that would allow them to both assess their own disease severity and communicate this information to their physicians.<xref ref-type="bibr" rid="b46-copd-6-289">46</xref></p>
      <p>Standardized assessments, beyond peak airflow (maximally forced expiration initiated at full inspiration) currently used to assess patients in clinical practice evaluate multidimensional domains (symptoms, physical, psychological, and social) affected by COPD. Examples of disease-specific instruments include the MRC dyspnea scale, the Clinical COPD Questionnaire (CCQ), and the CAT.<xref ref-type="bibr" rid="b46-copd-6-289">46</xref>&#x2013;<xref ref-type="bibr" rid="b48-copd-6-289">48</xref> These measures can be assessed in terms of their relative reliability, validity, responsiveness, acceptability, and feasibility in everyday clinical practice.<xref ref-type="bibr" rid="b25-copd-6-289">25</xref> Other questionnaires such as the SGRQ, CRQ, and Short Form 36-item Health Survey (SF-36) comprise many more questions and consequently are not suitable for use in daily clinical practice, so these questionnaires are not discussed further. A comprehensive review of available questionnaires is currently being undertaken by the International Primary Care Respiratory Group (<ext-link ext-link-type="uri" xlink:href="www.theipcrg.org/">www.theipcrg.org/</ext-link>).</p>
      <p>Questionnaires are precision instruments that can provide sensitive and specific information and, if sufficiently short and simple, can enable physicians in routine clinical practice to assess the health status of their patients accurately, thereby allowing improved COPD management.</p>
      <sec>
        <title>Medical research council dyspnea scale</title>
        <p>The MRC dyspnea scale, recommended by the Global Initiative for Chronic Obstructive Lung Disease (GOLD)<xref ref-type="bibr" rid="b2-copd-6-289">2</xref> and other national guidelines, was developed by Fletcher et al while studying the respiratory problems of Welsh coalminers in the 1940s.<xref ref-type="bibr" rid="b48-copd-6-289">48</xref>,<xref ref-type="bibr" rid="b49-copd-6-289">49</xref> It is short (comprises five dyspnea items) and has been in use for many years for grading the effect of breathlessness on daily activities. It is simple to administer because it allows patients to indicate the extent to which their breathlessness affects their mobility. However, it only measures one aspect of the patient experience (ie, perceived respiratory disability) and is poorly responsive to change.</p>
      </sec>
      <sec>
        <title>Clinical COPD questionnaire</title>
        <p>The CCQ (<xref ref-type="fig" rid="f3-copd-6-289">Figure 3</xref>) consists of three domains and 10 items, ie, symptoms (four items), functional state (four items), and mental state (two items). All scores range from 0&#x2013;6 (0, no impairment).<xref ref-type="bibr" rid="b47-copd-6-289">47</xref> The CCQ was developed in consultation with 32 patients in two countries, and item reduction performed in collaboration with 79 clinicians worldwide. Patients can complete the CCQ quickly (in approximately two minutes) and it is straightforward to score; this allows data to be instantly collected and processed, enabling its use in everyday practice, clinical trials, and quality-of-care monitoring. Three studies in the Netherlands, Italy, and Sweden provided strong supporting evidence for the reliability, validity, and responsiveness of the CCQ.<xref ref-type="bibr" rid="b47-copd-6-289">47</xref>,<xref ref-type="bibr" rid="b50-copd-6-289">50</xref>,<xref ref-type="bibr" rid="b51-copd-6-289">51</xref> A change in the total CCQ score of &#x2265;0.4 from one patient visit to the next is considered to be significant (ie, the minimum clinically important difference).<xref ref-type="bibr" rid="b52-copd-6-289">52</xref> The CCQ is freely available (in 53 languages) for use in clinical practice (<ext-link ext-link-type="uri" xlink:href="www.ccq.nl">www.ccq.nl</ext-link>).</p>
      </sec>
      <sec>
        <title>COPD assessment test</title>
        <p>The CAT (<xref ref-type="fig" rid="f4-copd-6-289">Figure 4</xref>) is a short (eight-item) and simple-to-administer patient-completed questionnaire designed for routine use in clinical practice. It covers a wide range of effects of COPD, including cough and sputum, chest symptoms, activity limitation, sleep, fatigue, and confidence leaving home. Patients can complete the CAT quickly (in approximately two minutes) by themselves in the doctor&#x2019;s waiting room. Development of the CAT involved consultation with a large number of patients at each stage of the process. Items covered in the CAT can help physicians measure the overall impact that COPD is having on patient wellbeing and daily life. Thus, the CAT provides a holistic measure of COPD health status;<xref ref-type="bibr" rid="b46-copd-6-289">46</xref> it should facilitate a fact-based, physician-patient dialog and improve communication to present a common understanding and grading of the impact of COPD. It is supported by strong evidence for reliability and by preliminary data for construct and discriminant validity;<xref ref-type="bibr" rid="b46-copd-6-289">46</xref> additional validity analyses are ongoing. The minimum clinically important difference in CAT score is yet to be established formally,<xref ref-type="bibr" rid="b53-copd-6-289">53</xref> but based upon mapping from the SGRQ at a population level it will be approximately 1.6 units. At the individual patient level, a change in CAT score of &#x2265;2 units will be clinically significant. The CAT is freely available (although GlaxoSmithKline owns the copyright to protect it from unauthorized changes) for use in daily clinical practice (<ext-link ext-link-type="uri" xlink:href="www.catestonline.org">www.catestonline.org</ext-link>).</p>
      </sec>
    </sec>
    <sec sec-type="conclusions">
      <title>Summary</title>
      <p>An increased understanding of the full impact of COPD on patients and their carers should enable physicians to provide targeted intervention and improve patients&#x2019; HRQoL.</p>
      <p>Care for patients with COPD can be optimized best by use of reliable, standardized measurements of overall disease impact. The measures should be appropriate to the question being addressed, sensitive to changes that are relevant to patients, capable of providing physicians with meaningful scores, and acceptable to both patients and health care providers.<xref ref-type="bibr" rid="b54-copd-6-289">54</xref> The questionnaires reviewed here have those attributes and are quick and easy to use during consultations. Incorporation of questionnaires such as these into the consultation process will enable improved patient-physician partnership decision-making, help prioritize patients for primary care review, and drive effective management of patients with COPD.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>Editorial support in the form of development of the manuscript first draft, collating author comments, and referencing was provided by Dr Richard Barry (Quintiles Medical Communications) and was funded by GlaxoSmithKline.</p>
    </ack>
    <fn-group>
      <fn>
        <p>
          <bold>Disclosure</bold>
        </p>
        <p>PWJ has received consultancy and advisory board fees from GlaxoSmithKline, AstraZeneca, Almirall, Boehringer Ingelheim, Roche, and Spiration; he has also received lecture fees from GlaxoSmithKline. DP has consultant arrangements with Boehringer Ingelheim, GlaxoSmithKline, Merck, Novartis, and Teva. He and/or his research team have received grants and support for research in respiratory disease from the following organizations in the past five years: UK National Health Service, Aerocrine, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Novartis, Nycomed, Pfizer, and Teva. He has spoken for Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Pfizer, and Teva. TVDM has participated as a speaker at several conferences financed by ALTANA, GlaxoSmithKline, and AstraZeneca. He has served on the advisory boards for Merck, AstraZeneca, and Nycomed. He has received research grants from ALTANA, AstraZeneca, and MSD.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="b1-copd-6-289">
        <label>1.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Mathers</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ma Fat</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <source>Global Burden of Disease 2000: Version 2 methods and results</source>
          <publisher-loc>Geneva, Switzerland</publisher-loc>
          <publisher-name>World Health Organization</publisher-name>
          <year>2002</year>
        </element-citation>
      </ref>
      <ref id="b2-copd-6-289">
        <label>2.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <collab>Global Initiative for Chronic Obstructive Lung Disease</collab>
          </person-group>
          <article-title>Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (updated 2009)</article-title>
          <publisher-name>Global Initiative for Chronic Obstructive Lung Disease</publisher-name>
          <year>2009</year>
          <comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://goldcopd.com/">http://goldcopd.com/</ext-link>. Accessed April 1, 2011.</comment>
        </element-citation>
      </ref>
      <ref id="b3-copd-6-289">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Menezes</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Perez-Padilla</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hallal</surname>
              <given-names>PC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Worldwide burden of COPD in high- and low-income countries. Part II. Burden of chronic obstructive lung disease in Latin America: The PLATINO study</article-title>
          <source>Int J Tuberc Lung Dis</source>
          <year>2008</year>
          <volume>12</volume>
          <fpage>709</fpage>
          <lpage>712</lpage>
          <pub-id pub-id-type="pmid">18544192</pub-id>
        </element-citation>
      </ref>
      <ref id="b4-copd-6-289">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>De Oca</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Talamo</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Halbert</surname>
              <given-names>RJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Frequency of self-reported COPD exacerbation and airflow obstruction in five Latin American cities: The Proyecto Latinoamericano de Investigacion en Obstruccion Pulmonar (PLATINO) study</article-title>
          <source>Chest</source>
          <year>2009</year>
          <volume>136</volume>
          <fpage>71</fpage>
          <lpage>78</lpage>
          <pub-id pub-id-type="pmid">19349388</pub-id>
        </element-citation>
      </ref>
      <ref id="b5-copd-6-289">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Buist</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Vollmer</surname>
              <given-names>WM</given-names>
            </name>
            <name>
              <surname>McBurnie</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Worldwide burden of COPD in high- and low-income countries. Part I. The burden of obstructive lung disease (BOLD) initiative</article-title>
          <source>Int J Tuberc Lung Dis</source>
          <year>2008</year>
          <volume>12</volume>
          <fpage>703</fpage>
          <lpage>708</lpage>
          <pub-id pub-id-type="pmid">18544191</pub-id>
        </element-citation>
      </ref>
      <ref id="b6-copd-6-289">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Braido</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Baiardini</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Menoni</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Disability in COPD and its relationship to clinical and patient-reported outcomes</article-title>
          <source>Curr Med Res Opin</source>
          <month>3</month>
          <day>8</day>
          <year>2011</year>
          <comment>[Epub ahead of print].</comment>
        </element-citation>
      </ref>
      <ref id="b7-copd-6-289">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jones</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Brusselle</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Dal Negro</surname>
              <given-names>RW</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Health-related quality of life in patients by COPD severity within primary care in Europe</article-title>
          <source>Respir Med</source>
          <year>2011</year>
          <volume>105</volume>
          <fpage>57</fpage>
          <lpage>66</lpage>
          <pub-id pub-id-type="pmid">20932736</pub-id>
        </element-citation>
      </ref>
      <ref id="b8-copd-6-289">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Decramer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Celli</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Kesten</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): A prespecified subgroup analysis of a randomised controlled trial</article-title>
          <source>Lancet</source>
          <year>2009</year>
          <volume>374</volume>
          <fpage>1171</fpage>
          <lpage>1178</lpage>
          <pub-id pub-id-type="pmid">19716598</pub-id>
        </element-citation>
      </ref>
      <ref id="b9-copd-6-289">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hurst</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Vestbo</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Anzueto</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Susceptibility to exacerbation in chronic obstructive pulmonary disease</article-title>
          <source>N Engl J Med</source>
          <year>2010</year>
          <volume>363</volume>
          <fpage>1128</fpage>
          <lpage>1138</lpage>
          <pub-id pub-id-type="pmid">20843247</pub-id>
        </element-citation>
      </ref>
      <ref id="b10-copd-6-289">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jenkins</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Calverley</surname>
              <given-names>PM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: Analysis from the randomised, placebo-controlled TORCH study</article-title>
          <source>Respir Res</source>
          <year>2009</year>
          <volume>10</volume>
          <fpage>59</fpage>
          <pub-id pub-id-type="pmid">19566934</pub-id>
        </element-citation>
      </ref>
      <ref id="b11-copd-6-289">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>ZuWallack</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>How are you doing? What are you doing? Differing perspectives in the assessment of individuals with COPD</article-title>
          <source>COPD</source>
          <year>2007</year>
          <volume>4</volume>
          <fpage>293</fpage>
          <lpage>297</lpage>
          <pub-id pub-id-type="pmid">17729076</pub-id>
        </element-citation>
      </ref>
      <ref id="b12-copd-6-289">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Buist</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>McBurnie</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Vollmer</surname>
              <given-names>WM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>International variation in the prevalence of COPD (the BOLD Study): A population-based prevalence study</article-title>
          <source>Lancet</source>
          <year>2007</year>
          <volume>370</volume>
          <fpage>741</fpage>
          <lpage>750</lpage>
          <pub-id pub-id-type="pmid">17765523</pub-id>
        </element-citation>
      </ref>
      <ref id="b13-copd-6-289">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maleki-Yazdi</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Lewczuk</surname>
              <given-names>CK</given-names>
            </name>
            <name>
              <surname>Haddon</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Choudry</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ryan</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Early detection and impaired quality of life in COPD GOLD stage 0: A pilot study</article-title>
          <source>COPD</source>
          <year>2007</year>
          <volume>4</volume>
          <fpage>313</fpage>
          <lpage>320</lpage>
          <pub-id pub-id-type="pmid">18027158</pub-id>
        </element-citation>
      </ref>
      <ref id="b14-copd-6-289">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kornmann</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Beeh</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Beier</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Newly diagnosed chronic obstructive pulmonary disease. Clinical features and distribution of the novel stages of the Global Initiative for Obstructive Lung Disease</article-title>
          <source>Respiration</source>
          <year>2003</year>
          <volume>70</volume>
          <fpage>67</fpage>
          <lpage>75</lpage>
          <pub-id pub-id-type="pmid">12584394</pub-id>
        </element-citation>
      </ref>
      <ref id="b15-copd-6-289">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Janse</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Gemke</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Uiterwaal</surname>
              <given-names>CS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Quality of life: Patients and doctors don&#x2019;t always agree: A meta-analysis</article-title>
          <source>J Clin Epidemiol</source>
          <year>2004</year>
          <volume>57</volume>
          <fpage>653</fpage>
          <lpage>661</lpage>
          <pub-id pub-id-type="pmid">15358393</pub-id>
        </element-citation>
      </ref>
      <ref id="b16-copd-6-289">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rennard</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Decramer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Calverley</surname>
              <given-names>PM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Impact of COPD in North America and Europe in 2000: Subjects&#x2019; perspective of Confronting COPD International Survey</article-title>
          <source>Eur Respir J</source>
          <year>2002</year>
          <volume>20</volume>
          <fpage>799</fpage>
          <lpage>805</lpage>
          <pub-id pub-id-type="pmid">12412667</pub-id>
        </element-citation>
      </ref>
      <ref id="b17-copd-6-289">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jones</surname>
              <given-names>PW</given-names>
            </name>
          </person-group>
          <article-title>Health status measurement in chronic obstructive pulmonary disease</article-title>
          <source>Thorax</source>
          <year>2001</year>
          <volume>56</volume>
          <fpage>880</fpage>
          <lpage>887</lpage>
          <pub-id pub-id-type="pmid">11641515</pub-id>
        </element-citation>
      </ref>
      <ref id="b18-copd-6-289">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mannino</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Homa</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Akinbami</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Ford</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Redd</surname>
              <given-names>SC</given-names>
            </name>
          </person-group>
          <article-title>Chronic obstructive pulmonary disease surveillance &#x2013; United States, 1971&#x2013;2000</article-title>
          <source>MMWR Surveill Summ</source>
          <year>2002</year>
          <volume>51</volume>
          <issue>6</issue>
          <fpage>1</fpage>
          <lpage>16</lpage>
        </element-citation>
      </ref>
      <ref id="b19-copd-6-289">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hansen</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Pedersen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Overvad</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The prevalence of chronic obstructive pulmonary disease among Danes aged 45&#x2013;84 years: Population-based study</article-title>
          <source>COPD</source>
          <year>2008</year>
          <volume>5</volume>
          <fpage>347</fpage>
          <lpage>352</lpage>
          <pub-id pub-id-type="pmid">19353348</pub-id>
        </element-citation>
      </ref>
      <ref id="b20-copd-6-289">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Domingo-Salvany</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lamarca</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ferrer</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2002</year>
          <volume>166</volume>
          <fpage>680</fpage>
          <lpage>685</lpage>
          <pub-id pub-id-type="pmid">12204865</pub-id>
        </element-citation>
      </ref>
      <ref id="b21-copd-6-289">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gudmundsson</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Gislason</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Janson</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Risk factors for rehospitalisation in COPD: Role of health status, anxiety and depression</article-title>
          <source>Eur Respir J</source>
          <year>2005</year>
          <volume>26</volume>
          <fpage>414</fpage>
          <lpage>419</lpage>
          <pub-id pub-id-type="pmid">16135721</pub-id>
        </element-citation>
      </ref>
      <ref id="b22-copd-6-289">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jones</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lareau</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mahler</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
          <article-title>Measuring the effects of COPD on the patient</article-title>
          <source>Respir Med</source>
          <year>2005</year>
          <volume>99</volume>
          <issue>Suppl B</issue>
          <fpage>S11</fpage>
          <lpage>S18</lpage>
          <pub-id pub-id-type="pmid">16236492</pub-id>
        </element-citation>
      </ref>
      <ref id="b23-copd-6-289">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oga</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nishimura</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tsukino</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sato</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hajiro</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Analysis of the factors related to mortality in chronic obstructive pulmonary disease: Role of exercise capacity and health status</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2003</year>
          <volume>167</volume>
          <fpage>544</fpage>
          <lpage>549</lpage>
          <pub-id pub-id-type="pmid">12446268</pub-id>
        </element-citation>
      </ref>
      <ref id="b24-copd-6-289">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Spencer</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>PW</given-names>
            </name>
          </person-group>
          <article-title>Time course of recovery of health status following an infective exacerbation of chronic bronchitis</article-title>
          <source>Thorax</source>
          <year>2003</year>
          <volume>58</volume>
          <fpage>589</fpage>
          <lpage>593</lpage>
          <pub-id pub-id-type="pmid">12832673</pub-id>
        </element-citation>
      </ref>
      <ref id="b25-copd-6-289">
        <label>25.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <collab>Patient-reported Health Instruments Group</collab>
          </person-group>
          <source>A structured review of patient-reported measures in relation to selected chronic conditions, perceptions of quality of care and carer impact</source>
          <publisher-loc>Oxford, UK</publisher-loc>
          <publisher-name>National Centre for Health Outcomes Development, Department of Health, University of Oxford</publisher-name>
          <year>2006</year>
        </element-citation>
      </ref>
      <ref id="b26-copd-6-289">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wagner</surname>
              <given-names>EH</given-names>
            </name>
          </person-group>
          <article-title>Chronic disease management: What will it take to improve care for chronic illness?</article-title>
          <source>Eff Clin Pract</source>
          <year>1998</year>
          <volume>1</volume>
          <fpage>2</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="pmid">10345255</pub-id>
        </element-citation>
      </ref>
      <ref id="b27-copd-6-289">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Adams</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>PK</given-names>
            </name>
            <name>
              <surname>Allan</surname>
              <given-names>PF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Systematic review of the chronic care model in chronic obstructive pulmonary disease prevention and management</article-title>
          <source>Arch Intern Med</source>
          <year>2007</year>
          <volume>167</volume>
          <fpage>551</fpage>
          <lpage>561</lpage>
          <pub-id pub-id-type="pmid">17389286</pub-id>
        </element-citation>
      </ref>
      <ref id="b28-copd-6-289">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bourbeau</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>van der</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
          <article-title>Promoting effective self-management programmes to improve COPD</article-title>
          <source>Eur Respir J</source>
          <year>2009</year>
          <volume>33</volume>
          <fpage>461</fpage>
          <lpage>463</lpage>
          <pub-id pub-id-type="pmid">19251792</pub-id>
        </element-citation>
      </ref>
      <ref id="b29-copd-6-289">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jones</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Donaldson</surname>
              <given-names>GC</given-names>
            </name>
            <name>
              <surname>Chavannes</surname>
              <given-names>NH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: The DOSE Index</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2009</year>
          <volume>180</volume>
          <fpage>1189</fpage>
          <lpage>1195</lpage>
          <pub-id pub-id-type="pmid">19797160</pub-id>
        </element-citation>
      </ref>
      <ref id="b30-copd-6-289">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Belza</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Steele</surname>
              <given-names>BG</given-names>
            </name>
            <name>
              <surname>Cain</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Seattle Obstructive Lung Disease Questionnaire: Sensitivity to outcomes in pulmonary rehabilitation in severe pulmonary illness</article-title>
          <source>J Cardiopulm Rehabil</source>
          <year>2005</year>
          <volume>25</volume>
          <fpage>107</fpage>
          <lpage>114</lpage>
          <pub-id pub-id-type="pmid">15818200</pub-id>
        </element-citation>
      </ref>
      <ref id="b31-copd-6-289">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ferrer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Alonso</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Morera</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Chronic obstructive pulmonary disease stage and health-related quality of life. The Quality of Life of Chronic Obstructive Pulmonary Disease Study Group</article-title>
          <source>Ann Intern Med</source>
          <year>1997</year>
          <volume>127</volume>
          <fpage>1072</fpage>
          <lpage>1079</lpage>
          <pub-id pub-id-type="pmid">9412309</pub-id>
        </element-citation>
      </ref>
      <ref id="b32-copd-6-289">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carrasco</surname>
              <given-names>GP</given-names>
            </name>
            <name>
              <surname>de Miguel</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Rejas</surname>
              <given-names>GJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Negative impact of chronic obstructive pulmonary disease on the health-related quality of life of patients. Results of the EPIDEPOC study</article-title>
          <source>Health Qual Life Outcomes</source>
          <year>2006</year>
          <volume>4</volume>
          <fpage>31</fpage>
          <pub-id pub-id-type="pmid">16719899</pub-id>
        </element-citation>
      </ref>
      <ref id="b33-copd-6-289">
        <label>33.</label>
        <element-citation publication-type="other">
          <person-group person-group-type="author">
            <name>
              <surname>Fletcher</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>van der Molen</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Salapatas</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Walsh</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>COPD uncovered: A report</article-title>
          <isbn>ISBN 978-0-9565537</isbn>
          <year>2009</year>
        </element-citation>
      </ref>
      <ref id="b34-copd-6-289">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Adams</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Chavannes</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ostergaard</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Price</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Exacerbations of chronic obstructive pulmonary disease &#x2013; a patients&#x2019; perspective</article-title>
          <source>Prim Care Respir J</source>
          <year>2006</year>
          <volume>15</volume>
          <fpage>102</fpage>
          <lpage>109</lpage>
          <pub-id pub-id-type="pmid">16701769</pub-id>
        </element-citation>
      </ref>
      <ref id="b35-copd-6-289">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wyrwich</surname>
              <given-names>KW</given-names>
            </name>
            <name>
              <surname>Metz</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Kroenke</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Measuring patient and clinician perspectives to evaluate change in health-related quality of life among patients with chronic obstructive pulmonary disease</article-title>
          <source>J Gen Intern Med</source>
          <year>2007</year>
          <volume>22</volume>
          <fpage>161</fpage>
          <lpage>170</lpage>
          <pub-id pub-id-type="pmid">17356981</pub-id>
        </element-citation>
      </ref>
      <ref id="b36-copd-6-289">
        <label>36.</label>
        <element-citation publication-type="webpage">
          <person-group person-group-type="author">
            <collab>Confronting COPD in America: Executive Summary</collab>
          </person-group>
          <comment><ext-link ext-link-type="uri" xlink:href="http://wwwaarcorg/resources/confronting_copd/exesum.pdf">http://wwwaarcorg/resources/confronting_copd/exesum.pdf</ext-link>. Accessed February 3, 2011.</comment>
        </element-citation>
      </ref>
      <ref id="b37-copd-6-289">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ries</surname>
              <given-names>AL</given-names>
            </name>
          </person-group>
          <article-title>Impact of chronic obstructive pulmonary disease on quality of life: The role of dyspnea</article-title>
          <source>Am J Med</source>
          <year>2006</year>
          <volume>119</volume>
          <fpage>12</fpage>
          <lpage>20</lpage>
          <pub-id pub-id-type="pmid">16996895</pub-id>
        </element-citation>
      </ref>
      <ref id="b38-copd-6-289">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oga</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nishimura</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tsukino</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Longitudinal deteriorations in patient reported outcomes in patients with COPD</article-title>
          <source>Respir Med</source>
          <year>2007</year>
          <volume>101</volume>
          <fpage>146</fpage>
          <lpage>153</lpage>
          <pub-id pub-id-type="pmid">16713225</pub-id>
        </element-citation>
      </ref>
      <ref id="b39-copd-6-289">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cruse</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>The impact of change in exercise tolerance on activities of daily living and quality of life in COPD: A patient&#x2019;s perspective</article-title>
          <source>COPD</source>
          <year>2007</year>
          <volume>4</volume>
          <fpage>279</fpage>
          <lpage>281</lpage>
          <pub-id pub-id-type="pmid">17729073</pub-id>
        </element-citation>
      </ref>
      <ref id="b40-copd-6-289">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kessler</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Stahl</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Vogelmeier</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Patient understanding, detection, and experience of COPD exacerbations: An observational, interview-based study</article-title>
          <source>Chest</source>
          <year>2006</year>
          <volume>130</volume>
          <fpage>133</fpage>
          <lpage>142</lpage>
          <pub-id pub-id-type="pmid">16840393</pub-id>
        </element-citation>
      </ref>
      <ref id="b41-copd-6-289">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Miravitlles</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Molina</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Naberan</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Factors determining the quality of life of patients with COPD in primary care</article-title>
          <source>Ther Adv Respir Dis</source>
          <year>2007</year>
          <volume>1</volume>
          <fpage>85</fpage>
          <lpage>92</lpage>
          <pub-id pub-id-type="pmid">19124350</pub-id>
        </element-citation>
      </ref>
      <ref id="b42-copd-6-289">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cote</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Pinto-Plata</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Kasprzyk</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Dordelly</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Celli</surname>
              <given-names>BR</given-names>
            </name>
          </person-group>
          <article-title>The 6-min walk distance, peak oxygen uptake, and mortality in COPD</article-title>
          <source>Chest</source>
          <year>2007</year>
          <volume>132</volume>
          <fpage>1778</fpage>
          <lpage>1785</lpage>
          <pub-id pub-id-type="pmid">17925409</pub-id>
        </element-citation>
      </ref>
      <ref id="b43-copd-6-289">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Esteban</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Quintana</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Moraza</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Impact of hospitalisations for exacerbations of COPD on health-related quality of life</article-title>
          <source>Respir Med</source>
          <year>2009</year>
          <volume>103</volume>
          <fpage>1201</fpage>
          <lpage>1208</lpage>
          <pub-id pub-id-type="pmid">19272762</pub-id>
        </element-citation>
      </ref>
      <ref id="b44-copd-6-289">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mannino</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Gagnon</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Petty</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Lydick</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Obstructive lung disease and low lung function in adults in the United States: Data from the National Health and Nutrition Examination Survey, 1988&#x2013;1994</article-title>
          <source>Arch Intern Med</source>
          <year>2000</year>
          <volume>160</volume>
          <fpage>1683</fpage>
          <lpage>1689</lpage>
          <pub-id pub-id-type="pmid">10847262</pub-id>
        </element-citation>
      </ref>
      <ref id="b45-copd-6-289">
        <label>45.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jones</surname>
              <given-names>PW</given-names>
            </name>
          </person-group>
          <article-title>Health status: What does it mean for payers and patients</article-title>
          <source>Proc Am Thorac Soc</source>
          <year>2006</year>
          <volume>3</volume>
          <fpage>222</fpage>
          <lpage>226</lpage>
          <pub-id pub-id-type="pmid">16636089</pub-id>
        </element-citation>
      </ref>
      <ref id="b46-copd-6-289">
        <label>46.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jones</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Harding</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Berry</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Development and first validation of the COPD Assessment Test</article-title>
          <source>Eur Respir J</source>
          <year>2009</year>
          <volume>34</volume>
          <fpage>648</fpage>
          <lpage>654</lpage>
          <pub-id pub-id-type="pmid">19720809</pub-id>
        </element-citation>
      </ref>
      <ref id="b47-copd-6-289">
        <label>47.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Van der</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Willemse</surname>
              <given-names>BW</given-names>
            </name>
            <name>
              <surname>Schokker</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Development, validity and responsiveness of the Clinical COPD Questionnaire</article-title>
          <source>Health Qual Life Outcomes</source>
          <year>2003</year>
          <volume>1</volume>
          <fpage>13</fpage>
          <pub-id pub-id-type="pmid">12773199</pub-id>
        </element-citation>
      </ref>
      <ref id="b48-copd-6-289">
        <label>48.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fletcher</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Elmes</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Fairbairn</surname>
              <given-names>MB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population</article-title>
          <source>Br Med J</source>
          <year>1959</year>
          <volume>2</volume>
          <fpage>257</fpage>
          <lpage>266</lpage>
          <pub-id pub-id-type="pmid">13823475</pub-id>
        </element-citation>
      </ref>
      <ref id="b49-copd-6-289">
        <label>49.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bestall</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Garrod</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease</article-title>
          <source>Thorax</source>
          <year>1999</year>
          <volume>54</volume>
          <fpage>581</fpage>
          <lpage>586</lpage>
          <pub-id pub-id-type="pmid">10377201</pub-id>
        </element-citation>
      </ref>
      <ref id="b50-copd-6-289">
        <label>50.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Damato</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bonatti</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Frigo</surname>
              <given-names>V</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Validation of the Clinical COPD questionnaire in Italian language</article-title>
          <source>Health Qual Life Outcomes</source>
          <year>2005</year>
          <volume>3</volume>
          <fpage>9</fpage>
          <pub-id pub-id-type="pmid">15698477</pub-id>
        </element-citation>
      </ref>
      <ref id="b51-copd-6-289">
        <label>51.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stallberg</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Nokela</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ehrs</surname>
              <given-names>PO</given-names>
            </name>
            <name>
              <surname>Hjemdal</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Jonsson</surname>
              <given-names>EW</given-names>
            </name>
          </person-group>
          <article-title>Validation of the clinical COPD Questionnaire (CCQ) in primary care</article-title>
          <source>Health Qual Life Outcomes</source>
          <year>2009</year>
          <volume>7</volume>
          <fpage>26</fpage>
          <pub-id pub-id-type="pmid">19320988</pub-id>
        </element-citation>
      </ref>
      <ref id="b52-copd-6-289">
        <label>52.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kocks</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Tuinenga</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Uil</surname>
              <given-names>SM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Health status measurement in COPD: The minimal clinically important difference of the clinical COPD questionnaire</article-title>
          <source>Respir Res</source>
          <year>2006</year>
          <volume>7</volume>
          <fpage>62</fpage>
          <pub-id pub-id-type="pmid">16603063</pub-id>
        </element-citation>
      </ref>
      <ref id="b53-copd-6-289">
        <label>53.</label>
        <element-citation publication-type="webpage">
          <person-group person-group-type="author">
            <collab>Healthcare professional user guide</collab>
          </person-group>
          <article-title>COPD Assessment Test: Expert guidance on frequently asked questions</article-title>
          <month>9</month>
          <year>2009</year>
          <comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://catestonline.co.uk/images/CAT_Expert%20Guidance_Issue1_2009.pdf">http://catestonline.co.uk/images/CAT_Expert%20Guidance_Issue1_2009.pdf</ext-link>. Accessed on April 1, 2011.</comment>
        </element-citation>
      </ref>
      <ref id="b54-copd-6-289">
        <label>54.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Horne</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Price</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Cleland</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Can asthma control be improved by understanding the patient&#x2019;s perspective?</article-title>
          <source>BMC Pulm Med</source>
          <year>2007</year>
          <volume>7</volume>
          <fpage>8</fpage>
          <pub-id pub-id-type="pmid">17518999</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="f1-copd-6-289" position="float">
      <label>Figure 1</label>
      <caption>
        <p>Symptom frequency in individuals with COPD (evaluation of worst three-month period in past year). Patients participating in the Confronting COPD in America survey were asked about the frequency of their symptoms during their worst three-month period in the past year (ie, &#x201C;Has there been any three-month period in the past year when you experienced &#x2026; [read item] &#x2013; every day, most days a week, a few days a week, a few days a month, less than that?&#x201D;). A high proportion of patients reported that they frequently experienced specific disease-associated outcomes during their worst period in the past year.<xref ref-type="bibr" rid="b36-copd-6-289">36</xref></p>
        <p>Reproduced with permission from GlaxoSmithKline.</p>
      </caption>
      <graphic xlink:href="copd-6-289f1"/>
    </fig>
    <fig id="f2-copd-6-289" position="float">
      <label>Figure 2</label>
      <caption>
        <p>Relationship between health status as measured by the SGRQ, and FEV<sub>1</sub> and GOLD stage. Patients&#x2019; perception of symptoms and health-related quality of life, as assessed by the SGRQ, were not well correlated with objective pulmonary function measurements, such as FEV<sub>1</sub> and GOLD stage.</p>
        <p>Adapted from Jones PW. Health status measurement in chronic obstructive pulmonary disease. <italic>Thorax</italic>. 2001;56:880&#x2013;887 with permission from the BMJ Publishing Group Limited.<xref ref-type="bibr" rid="b17-copd-6-289">17</xref></p>
        <p><bold>Abbreviations:</bold> SGRQ, St George&#x2019;s Respiratory Questionnaire; FEV<sub>1</sub>, forced expiratory volume in one second; GOLD, Global Initiative for Chronic Obstructive Lung Disease.</p>
      </caption>
      <graphic xlink:href="copd-6-289f2"/>
    </fig>
    <fig id="f3-copd-6-289" position="float">
      <label>Figure 3</label>
      <caption>
        <p>The clinical COPD questionnaire.</p>
        <p>Reproduced with permission from Thys van der Molen.</p>
      </caption>
      <graphic xlink:href="copd-6-289f3"/>
    </fig>
    <fig id="f4-copd-6-289" position="float">
      <label>Figure 4</label>
      <caption>
        <p>The COPD assessment test.</p>
        <p>Reproduced with permission from GlaxoSmithKline.</p>
      </caption>
      <graphic xlink:href="copd-6-289f4"/>
    </fig>
  </floats-group>
</article>
